连接点:微RNA如何将喘和动脉样硬化联系起来
Răzvan-Ionuț Zimbru1,2, Elena-Larisa Zimbru1,2,3, Florina-Maria Bojin1,2,4
1Center of Immuno-Physiology and Biotechnologies, Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
International journal of molecular sciences
|May 7, 2025
概括
微RNAs (miRNAs) 通过共享的炎症途径将喘和动脉样硬化联系起来. 针对这些常见的miRNAs提供了整合治疗的潜力,并改善了呼吸道和心血管疾病的患者结果.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 喘和动脉样硬化是具有明显病理的慢性炎症性疾病.
- 重叠的炎症机制表明,一个共同的监管框架可能会将这些疾病联系在一起.
- 微RNAs (miRNAs) 是基因表达的关键调节者,也是这种联系的潜在媒介.
研究的目的:
- 审查miRNAs在喘和动脉样硬化之间的相互作用中的作用.
- 识别参与共享炎症途径,免疫调节和血管重塑的特定miRNAs.
- 探索miRNAs作为生物标志物和治疗点的潜力.
主要方法:
- 文献综述侧重于与喘和动脉样硬化有关的miRNAs.
- 分析miRNA参与炎症路径,免疫细胞功能和血管重塑.
- 讨论特定的miRNAs (例如,miR-155,miR-21,miR-146a) 和它们的功能.
主要成果:
- 常见的miRNAs参与调节炎性细胞因子产生和T细胞分化.
- 这些miRNAs影响呼吸系统 (喘) 和心血管 (动脉样硬化) 的健康.
- 特定的miRNA如miR-155,miR-21和miR-146a因其作用而被突出显示.
结论:
- 常见的miRNAs代表了喘和动脉样硬化的潜在生物标志物.
- 针对这些共享的miRNAs可能会导致新的综合治疗策略.
- 需要进一步的研究来验证基于miRNA的干预措施对联合治疗方法的有效性.
相关概念视频
MicroRNAs
21.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.0K
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma: Pathogenesis and Management
234
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
234
Inflammation
51.2K
Overview
51.2K
The JAK-STAT Signaling Pathway
8.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.4K


